CLOV · Clover Health Investments, Corp. — research history

Stage produced output that could not be parsed as a valid JSON object. ~6h cooldown before retry.

{"symbol":"CLOV","company":"Clover Health Investments, Corp.","investigation_summary":"CLOV has undergone a dramatic +87% price appreciation driven by a court-ordered CMS Star Rating recalculation (3.5→4.5 stars for its PPO contract covering 97%+ of members), Q1 2026 GAAP profitability ($0.05/share vs est. $0.07), and analyst upgrades. The stock is near all-time highs with forward P/E of ~50x — ri

CLOV surged ~180% YTD following a Georgia District Court ruling on May 29, 2026 ordering CMS to recalculate its 2026 Star Rating for Contract H5141 (covering 97%+ of members), resulting in an upgrade from 3.5 to 4.5 Stars — the specific catalyst driving the move. The investigation trigger flagged 4 Form 4s in 14 days, but all were automated sell-to-cover or 10b5-1 plan sales; no discretionary open-market insider purchases (code P) were found among any of the 25 recent filings going back months. No mispricing exists: CLOV trades at 47.4x forward P/E vs. sector median ~15-18x for Medicare Advantage insurers, with a forward EV/EBITDA deeply negative and no positive earnings until recently (Q1 2026 first profitable quarter). The stock hit an all-time high on June 11 post-courtruling and has pulled back modestly — momentum is extended (RSI 69) with the price 8% below the 52-week high. Options flow is net bullish ($45K call bias) but no whale blocks. No edge in data; fully-valued at an extreme premium to peers with technical overbought conditions.

CLOV has experienced a dramatic ~150% run from its March lows to a new 52-week high of $4.18 following Q1 2026 profitability ($27.3M GAAP net income) and a court win over CMS/HHS on Star Ratings (May 29, 2026). However, the investigation trigger is misleading: the Form 4 cluster in recent weeks consists almost entirely of OPEN-MARKET SALES and TAX-WITHHOLDING VESTS by insiders — NOT purchases. CEO Andrew Toy and Interim CFO Thornton had RSU vesting events triggering tax withholding sells; Director Edwards and executives Wai/Priest sold at $3.42-$3.99. There are zero open-market purchase transactions (code P) among the recent filings. The stock trades at a 41.8x forward P/E with negative EBITDA, RSI at 84.9 (deeply overbought), and analysts target only $2.82. The bull thesis (Medicare Advantage growth + Clover Assistant platform + Counterpart SaaS licensing) is real but already priced in at this valuation and momentum level.

After reading all Form 4 filings from the trigger window and cross-referencing them against actual transaction codes (P=open-market purchase), I found that ALL recent insider activity is either RSU grants (code A) or tax-withholding sales on vesting (codes F/S). There are zero open-market purchases by insiders in the past 90 days. One officer sale — Brady Priest selling ~$345K at $3.52 on May 13 via code S (open market sale) — is the only genuine bearish signal from smart money, and it was tax-withholding-driven rather than a conviction sale. The company did deliver a strong Q1 2026 with first-ever GAAP net income ($27.3M) and 62% revenue growth, but this appears fully captured in the price: the stock is up ~48% in 30 days, RSI is at 79.6 (deeply overbought), and it trades at a forward P/E of 36x versus sector peers at 15-20x.

After thorough examination of all 30 recent Form-4 filings, the triggering 'Form 4 cluster' is almost entirely RSU tax-withholding activity (code F) — not open-market buys. The sole genuine sale was a mid-level executive offloading $345K at near-52-week-high prices. Combined with an elevated forward P/E of ~34x versus sector leader Humana at ~20x, RSI overbought at 75.6, no CEO/CFO purchases in any window, and a recent CFO transition as a minor negative signal, the data presents neither a mispricing nor a credible insider edge for the long side.